NASDAQ:RKDA Arcadia Biosciences (RKDA) Stock Price, News & Analysis $3.84 -0.13 (-3.27%) Closing price 08/27/2025 04:00 PM EasternExtended Trading$3.85 +0.01 (+0.26%) As of 08/27/2025 06:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Arcadia Biosciences Stock (NASDAQ:RKDA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Arcadia Biosciences alerts:Sign Up Key Stats Today's Range$3.84▼$3.9050-Day Range$3.84▼$4.8252-Week Range$2.53▼$10.31Volume5,886 shsAverage Volume5,136 shsMarket Capitalization$5.26 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Arcadia Biosciences, Inc. produces and markets plant-based food and beverage products in the United States. The company develops crop improvements primarily in wheat to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients. Its food, beverage, and body case products include GoodWheat, Zola coconut water, ProVault topical pain relief, and SoulSpring. The company was incorporated in 2002 and is headquartered in Dallas, Texas. Read More Arcadia Biosciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks24th Percentile Overall ScoreRKDA MarketRank™: Arcadia Biosciences scored higher than 24% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Arcadia Biosciences. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Arcadia Biosciences is -0.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Arcadia Biosciences is -0.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioArcadia Biosciences has a P/B Ratio of 1.16. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Arcadia Biosciences' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.51% of the float of Arcadia Biosciences has been sold short.Short Interest Ratio / Days to CoverArcadia Biosciences has a short interest ratio ("days to cover") of 1.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Arcadia Biosciences has recently decreased by 6.79%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldArcadia Biosciences does not currently pay a dividend.Dividend GrowthArcadia Biosciences does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted1.51% of the float of Arcadia Biosciences has been sold short.Short Interest Ratio / Days to CoverArcadia Biosciences has a short interest ratio ("days to cover") of 1.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Arcadia Biosciences has recently decreased by 6.79%, indicating that investor sentiment is improving significantly. News and Social Media4.4 / 5News SentimentN/A News SentimentArcadia Biosciences has a news sentiment score of 1.88. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.99 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Arcadia Biosciences this week, compared to 0 articles on an average week.Search Interest3 people have searched for RKDA on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.MarketBeat Follows2 people have added Arcadia Biosciences to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Arcadia Biosciences insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.80% of the stock of Arcadia Biosciences is held by insiders.Percentage Held by InstitutionsOnly 17.73% of the stock of Arcadia Biosciences is held by institutions.Read more about Arcadia Biosciences' insider trading history. Receive RKDA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Arcadia Biosciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. RKDA Stock News HeadlinesArcadia Biosciences, Inc.: Arcadia Biosciences (RKDA) Announces Second Quarter and First Half 2025 Financial Results and Business HighlightsAugust 15, 2025 | finanznachrichten.deArcadia Biosciences (RKDA) Announces Second Quarter and First Half 2025 Financial Results and Business HighlightsAugust 14, 2025 | globenewswire.comBreaking News: Trump Could Unlock $21 Trillion for Everyday AmericansPresident Trump just signed a new law… That could unlock $21 trillion for everyday folks like you… And potentially impact every checking and savings account in America. | Brownstone Research (Ad)RKDA Arcadia Biosciences, Inc.May 24, 2025 | seekingalpha.comArcadia Biosciences, Inc. (RKDA) Q1 2025 Earnings Call TranscriptMay 11, 2025 | seekingalpha.comARCADIA BIOSCIENCES Earnings Results: $RKDA Reports Quarterly EarningsMay 10, 2025 | nasdaq.comArcadia Biosciences, Inc. (NASDAQ:RKDA) Q1 2025 Earnings Call TranscriptMay 10, 2025 | msn.comArcadia Biosciences Inc (RKDA) Q1 2025 Earnings Call Highlights: Strong Zola Sales and ...May 9, 2025 | finance.yahoo.comSee More Headlines RKDA Stock Analysis - Frequently Asked Questions How have RKDA shares performed this year? Arcadia Biosciences' stock was trading at $5.92 at the start of the year. Since then, RKDA shares have decreased by 35.1% and is now trading at $3.84. How were Arcadia Biosciences' earnings last quarter? Arcadia Biosciences, Inc. (NASDAQ:RKDA) released its quarterly earnings results on Thursday, August, 14th. The basic materials company reported $0.02 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.79) by $0.81. The basic materials company had revenue of $1.46 million for the quarter, compared to analysts' expectations of $1.60 million. Arcadia Biosciences had a negative net margin of 139.36% and a negative trailing twelve-month return on equity of 34.75%. When did Arcadia Biosciences' stock split? Arcadia Biosciences's stock reverse split on Wednesday, January 24th 2018.The 1-20 reverse split was announced on Tuesday, January 23rd 2018. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, January 23rd 2018. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. When did Arcadia Biosciences IPO? Arcadia Biosciences (RKDA) raised $66 million in an initial public offering (IPO) on Friday, May 15th 2015. The company issued 8,200,000 shares at a price of $8.00 per share. Credit Suisse, J.P. Morgan and Piper Jaffray served as the underwriters for the IPO. How do I buy shares of Arcadia Biosciences? Shares of RKDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Arcadia Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Arcadia Biosciences investors own include NVIDIA (NVDA), Meta Platforms (META), PayPal (PYPL), GE Aerospace (GE), Arista Networks (ANET), Advanced Micro Devices (AMD) and CrowdStrike (CRWD). Company Calendar Last Earnings8/14/2025Today8/27/2025Next Earnings (Estimated)11/13/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryAgriculture Current SymbolNASDAQ:RKDA CIK1469443 Webwww.arcadiabio.com Phone(530) 756-7077Fax530-756-7027Employees60Year Founded2002Profitability EPS (Trailing Twelve Months)($4.28) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$7.04 million Net Margins-139.36% Pretax Margin-130.77% Return on Equity-34.75% Return on Assets-20.91% Debt Debt-to-Equity RatioN/A Current Ratio4.12 Quick Ratio3.31 Sales & Book Value Annual Sales$5.05 million Price / Sales1.04 Cash FlowN/A Price / Cash FlowN/A Book Value$3.32 per share Price / Book1.16Miscellaneous Outstanding Shares1,370,000Free Float1,342,000Market Cap$5.26 million OptionableNot Optionable Beta0.51 Social Links The 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report This page (NASDAQ:RKDA) was last updated on 8/28/2025 by MarketBeat.com Staff From Our PartnersBuffett, Gates and Bezos Dumping StocksThe world's wealthiest individuals are making huge moves with their money. Warren Buffett just liquidated b...Banyan Hill Publishing | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredSmall Washington, DC Group Could Crash US StocksNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arcadia Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arcadia Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.